Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Probenecid and Ciclosporin on SNAC Pharmacokinetics
NCT03466567Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2018
- Primary completion
- Jul 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the SNAC plasma concentration-time curve from time 0 to time of the last quantifiable concentration and Maximum observed SNAC plasma concentration. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03466567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03466567.